Zinc Deficiency Clinical Trial
Official title:
Oral Zinc Supplementation in Children With Dilated Cardiomyopathy : Aprospective Cohort Study in Assiut ,Egypt.
The aim of this study is to detect effect of oral zinc supplementation in pediatric patients with dilated cardiomyopathy.
Cardiomyopathies are group of heart diseases that influence cardiac muscles directly and are not related to hypertension, congenital, valvular and pericardial diseases. The most common type of cardiomyopathy is dilate cardiomyopathy. Dilated cardiomyopathy usually manifests as chronic systolic heart failure leading to arrhythmias and sudden death. Trace elements are known to have a key role in myocardial metabolism. The human heart requires energy from micro and macro nutrients both to regenerate proteins and cells, and to support cyclic contractions. Heart failure is associated with neuro-hormonal activation leading to elevated levels of inflammatory markers and oxidative stress. Zinc is an essential micronutrient that impacts the cardiovascular system. There are multiple potential pathophysiologic causes for zinc deficiency in heart failure as result of impaired micronutrient consumption, hyper inflammatory state, diminished absorption and hyperzincuria from heart failure medications. Zinc deficiency may play a role as primary and possible reversible cause of dilated cardiomyopathy. Plasma zinc levels have been reported in multiple observational studies of patients with heart failure particularly in studies of idiopathic dilated cardiomyopathy, serum zinc levels have been found to be low. A small but growing body of evidence suggesting the role for oral zinc supplementation in the management of dilated cardiomyopathy however further evaluation of the impact on outcome is needed. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT03353662 -
Sub Regional Micronutrient Survey in Ethiopia
|
||
Completed |
NCT02126293 -
Correction of Zinc Deficiency in Children With Chronic Kidney Disease and Kidney Transplant
|
Phase 3 | |
Terminated |
NCT01472211 -
Water-based Zinc Intervention Trial in Zinc Deficient Children
|
Phase 0 | |
Completed |
NCT01061307 -
An Efficacy Trial of Iron, Zinc and Vitamin A Fortified Rice in Children in Satun, Thailand
|
Phase 0 | |
Recruiting |
NCT03421314 -
Effect of Zinc and Selenium Supplementation on HIV+ Individuals on Antiretroviral Treatment.
|
N/A | |
Completed |
NCT02292303 -
Clinical Trial to Determine the Bioavailability of Three Different Zinc Preparations
|
N/A | |
Completed |
NCT02241330 -
Efficacy of Zn Biofortified Wheat in Improving Zn Status in Indian School Children With Low Zn Status
|
N/A | |
Completed |
NCT01221129 -
Zinc and the Synthesis of Zinc Binding Proteins (Protocol B)
|
N/A | |
Completed |
NCT04632771 -
Nutritional Status and Bouillon Use in Northern Ghana
|
||
Recruiting |
NCT05236374 -
Effects of Daily Beef Intake, as a Component of a Heart-Healthy Diet on Cellular Zinc
|
N/A | |
Completed |
NCT02758444 -
Effects of EED on Zn Absorption and Retention in Children From a MNP
|
N/A | |
Completed |
NCT02760095 -
Effects of EED on Zn Absorption and Retention in Children From a Standard Dose
|
||
Completed |
NCT02233764 -
Effect of Iron/Zinc-Biofortified Pearl Millet on Growth and Immunity in Children Aged 12-18 Months in India
|
N/A | |
Recruiting |
NCT05527899 -
Zinc Intervention in Elderly for Prevention of Pneumonia
|
Phase 2/Phase 3 | |
Terminated |
NCT04983667 -
Zinc-AA Supplementation During Pregnancy & Lactation to Assess Effects on ASD Prevalence in Offspring
|
N/A | |
Completed |
NCT03293641 -
Zinc Supplementation in Children With Sickle Cell Disease in Western Kenya
|
N/A | |
Completed |
NCT05778383 -
Zinc Supplementation Impact in Acute COVID-19 Clinical Outcomes
|
Phase 4 | |
Completed |
NCT04559152 -
Zinc Supplementation During Pregnancy: Analysis of Maternal Serum Zinc, Cord Blood Osteocalcin and Neonatal Birth Length
|
N/A | |
Completed |
NCT01062347 -
A Novel Bio-marker of Zinc Status
|
Phase 1 | |
Recruiting |
NCT05085834 -
Zinc Effect on Inflammation and Cardiovascular Risk in HIV
|
Early Phase 1 |